Skip to main content
Fig. 1 | Genome Biology

Fig. 1

From: Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia

Fig. 1

Candidate core pan-cancer drivers of metabolic dysregulation and hypoxia association. a For each candidate driver, the cumulative bar chart shows the inclusion frequencies representing the number of cancer types whereby mRNA and copy number profiles were correlated. The inclusion criterion was arbitrarily set to a minimum of three cancers. The heat map shows the extent of genomic aberrations for the selected candidate drivers as well as the corresponding cancer types. The intensity indicates the fraction of the cohort in which a given gene has either a gain or amplification. The rows (tumour types) were ordered using hierarchical clustering. b The distribution of core candidate metabolic drivers in statistically enriched compartments of metabolic pathways. The number in each segment indicates the metabolic genes present in that compartment. The dashed arcs (with numbers) indicate the number of genes shared between the compartments (Additional file 1 and Additional file 2: Table S7). c Cancer-wise mRNA correlations (Spearman’s correlation coefficients) of core metabolic signature (44 genes, Sig. group) and hypoxia score and compared with the correlations between non-selected metabolic genes (Other) and hypoxia score. For each cancer type, the distribution of both sets of correlations was compared using a one-sided Wilcoxon test and the P values are displayed. Box plots are sorted (high on the left to low on the right) by the median correlation coefficient in the signature (Sig.) set of scores. To avoid bias, three genes common to the metabolism signature and hypoxia signature and another up to 17 genes (depending upon the cancer type) common to the non-selected metabolic group and hypoxia signature were removed. BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, LUAD lung adenocarcinoma, COADREAD colorectal adenocarcinoma, GBM glioblastoma multiforme, UCEC uterine corpus endometrial carcinoma, KIRC Kidney renal clear cell carcinoma, LUSC lung squamous cell carcinoma, HNSC head and neck squamous cell carcinoma, OV Ovarian serous cystadenocarcinoma

Back to article page